Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04524689 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab…(CARMEN-LC05) | Phase 2 | terminated | Aug 24, 2020 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated… | Phase 1 / Phase 2 | terminated | Jul 21, 2022 | BerGenBio ASA | Lack of efficacy | Efficacy / futility |
| NCT05513703 | A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in… | Phase 2 | terminated | Aug 24, 2022 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and… | Phase 1 | terminated | Sep 10, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07284890.… | Safety / toxicity |
| NCT04926831 | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC(Geometry-N) | Phase 2 | terminated | Jun 15, 2021 | Novartis Pharmaceuticals | The study was terminated early due to recruitment challenges. | Enrollment / accrual |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Phase 1 | terminated | Jul 29, 2021 | Taiho Oncology, Inc. | After careful review of Taiho's ongoing portfolio and data obtained so far in the context of… | Safety / toxicity |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin… | Phase 1 | terminated | Apr 7, 2022 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jun 7, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects… | Phase 3 | terminated | Nov 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade…(SABRseq) | Phase 1 | terminated | Oct 12, 2017 | Peter MacCallum Cancer Centre, Australia | Slow patient accrual | Enrollment / accrual |
| NCT05472623 | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab(Neo-Kan) | Phase 2 | withdrawn | Jul 25, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | no participants enrolled across sites | Enrollment / accrual |
| NCT00210171 | Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer(BIB 01) | Phase 2 | withdrawn | Sep 21, 2005 | Institut Bergonié | The study was withdrawn due to logistic issues. | Other (stated, no rule matched) |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic… | Phase 1 / Phase 2 | terminated | Dec 22, 2022 | Suzhou Junjing BioSciences Co., Ltd. | Due to the adjustment of the R\&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to… | Sponsor / business decision |
| NCT05577715 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell… | Phase 2 | terminated | Oct 13, 2022 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT05245071 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5…(CARMEN-LC06) | Phase 2 | terminated | Feb 17, 2022 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic… | Phase 2 | withdrawn | Aug 15, 2024 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus… | Phase 2 | terminated | Oct 9, 2020 | GlaxoSmithKline | Trial terminated by GSK for strategic reasons, after all participants completed treatment. This… | Safety / toxicity |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With…(TUXEDO-5) | Phase 2 | withdrawn | Nov 6, 2024 | MedSIR | The clinical trial has not been approved by the regulatory authority. | Other (stated, no rule matched) |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by… | Phase 2 | withdrawn | Jun 26, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT05617313 | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell… | Phase 2 | terminated | Nov 15, 2022 | Jeffrey Clarke | Study did not meet the criteria for continuation after interim analysis | Efficacy / futility |
| NCT05691829 | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV…(IRRADIATE-Lung) | Phase 2 | terminated | Jan 20, 2023 | NYU Langone Health | Terminated due to insufficient enrollment. | Enrollment / accrual |
| NCT04615884 | Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients(CH:II) | N/A | withdrawn | Nov 4, 2020 | Lady Davis Institute | unable to secure the funding despite multiple grant applications | Funding |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT03087708 | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | Phase 2 | terminated | Mar 22, 2017 | Alliance for Clinical Trials in Oncology | Insufficient accrual | Enrollment / accrual |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer… | Phase 1 | terminated | Mar 29, 2023 | Transgene | Sponsor decision not related to safety | Safety / toxicity |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | — | terminated | Nov 14, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus… | Phase 2 | terminated | Dec 17, 2018 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | Phase 1 | terminated | Oct 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT04921358 | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or… | Phase 3 | terminated | Jun 10, 2021 | BeiGene | Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to… | Safety / toxicity |
| NCT06643117 | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as…(Lotus) | Phase 3 | terminated | Oct 16, 2024 | Formycon AG | Formycon concluded that continuing the trial is no longer necessary for the development and… | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT05251805 | The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery | N/A | terminated | Feb 23, 2022 | Universitair Ziekenhuis Brussel | Initial observations suggest challenges in performing bone marrow aspiration in the first few… | Enrollment / accrual |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | Phase 1 / Phase 2 | terminated | Mar 29, 2021 | Bridge Biotherapeutics, Inc. | Sponsor's decision considering the changing treatment landscape for NSCLC | Sponsor / business decision |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT03505710 | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated…(DESTINY-Lung01) | Phase 2 | terminated | Apr 23, 2018 | Daiichi Sankyo | Last participant transitioned to alternative study. | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04441138 | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III…(ESR1814205) | Phase 2 | terminated | Jun 22, 2020 | Rush University Medical Center | Institutional constraints due to research staffing and diminished data safety monitoring… | Safety / toxicity |
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small… | Phase 2 | withdrawn | May 3, 2023 | City of Hope Medical Center | no accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 29, 2025source: clinicaltrials